Pluristem Therapeutics (NASDAQ: PSTI) and Charles River Laboratories International (NYSE:CRL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.
This is a breakdown of current ratings for Pluristem Therapeutics and Charles River Laboratories International, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Charles River Laboratories International||0||5||4||0||2.44|
Pluristem Therapeutics presently has a consensus price target of $4.13, indicating a potential upside of 176.85%. Charles River Laboratories International has a consensus price target of $101.28, indicating a potential downside of 7.85%. Given Pluristem Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Pluristem Therapeutics is more favorable than Charles River Laboratories International.
Insider and Institutional Ownership
4.5% of Pluristem Therapeutics shares are held by institutional investors. Comparatively, 95.4% of Charles River Laboratories International shares are held by institutional investors. 7.0% of Pluristem Therapeutics shares are held by company insiders. Comparatively, 2.2% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Pluristem Therapeutics and Charles River Laboratories International’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Pluristem Therapeutics||N/A||N/A||-$25.84 million||($0.32)||-4.66|
|Charles River Laboratories International||$1.81 billion||2.89||$435.89 million||$3.81||28.85|
Charles River Laboratories International has higher revenue and earnings than Pluristem Therapeutics. Pluristem Therapeutics is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.
This table compares Pluristem Therapeutics and Charles River Laboratories International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Charles River Laboratories International||10.13%||27.02%||8.84%|
Risk and Volatility
Pluristem Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.
Charles River Laboratories International beats Pluristem Therapeutics on 8 of the 11 factors compared between the two stocks.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.
About Charles River Laboratories International
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company’s clients’ manufacturing activities.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.